Marys Group Korea Co., Ltd. (CEO Kim Jong-sook) announced that it will participate in the 3th International Medical Equipment and Hospital Equipment Exhibition ‘KIMES 23’, which will be held at COEX, Seoul from March 26rd (Thursday) to 38th (Sunday).
Meris Group, which was founded in 2008 and celebrates its 15th anniversary this year, is a company specializing in Chinese NMPA medical device licensing agency and is headquartered in Beijing, where the Chinese NMPA General Administration is located.
‘Merrys Group Korea’, a Korean corporation established by the group in 2015, is known to be the first in Korea to be 100% invested by a local NMPA licensing agency in China. Since the establishment of the corporation, we have been providing one-stop Chinese certification solutions and services such as CRO and SMO, and in April 2021, we were selected as a consulting agency for the overseas standard certification acquisition support project and began to provide consulting services for Chinese NMPA medical device licensing for small and medium-sized businesses. did.
In this exhibition, Meris Group Korea introduces its medical device production system, registration service, product testing, clinical evaluation, clinical trial, and licensing service for all procedures including SMO. Their service is characterized by its specialized capabilities in Chinese certification technical consulting services in three fields, including medical devices, health functional foods (foods for special medical purposes), and cosmetics. The company explains that this will provide customers with comprehensive and professional technical consulting.
Based on this service base, Meris Group has accumulated more than 800 clients to date and has supported the acquisition of more than 1,500 certificates in total. In particular, the official emphasized that the company has efficiently assisted domestic medical device and medi-cosmetics companies in entering the Chinese market by ensuring excellent capabilities and performance in the field of clinical evaluation report (CER) writing.
An official from Meris Group Korea said, “From 2015 to the present, we have listened to the difficulties faced by numerous domestic medical device manufacturers in the process of attempting to enter the Chinese market, and have been working with our headquarters in Beijing for many years to resolve these issues.” He added, “NMPA, the first gateway to that goal. “We have participated in KIMES every year and conducted related consultations to help with licensing registration, and this year we will also help the domestic industry explore greater possibilities,” he said, explaining the reason for participating in the exhibition.
He continued, “We plan to quickly respond to new laws and testing standards in 2023 to effectively and efficiently help with NMPA certification in China, which everyone considers difficult,” and added, “We plan to deliver accurate awareness regarding Chinese licensing through professional and accurate consulting.” “We are trying,” he added.
On the other hand, KIMES is an exhibition specializing in medical devices and hospital facilities that has grown steadily with the development of the Korean medical industry since its first meeting in 1980. It has transformed into a technology-intensive high-tech industry such as rehabilitation medicine.
KIMES 2023 will feature new technologies and new products suitable for the era of convergence, such as smart healthcare in the era of the 4th Industrial Revolution, robotic medicine and eco-friendly medical waste facilities, cutting-edge hospital facilities, medical information systems combined with IT technology, and the automobile industry for rapid patient transportation. presents. In addition, it provides a variety of information, including seminars on medical technology, new technology, and overseas marketing, as well as domestic medical industry policy seminars that will show the latest information and direction of the medical industry.